Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research
The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT) GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 — The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic…
Liam, Growing Up with CMT4C
Liam’s CMT Story: Growing Up with CMT4C As an infant, I lived with many challenges, including the inability to stand independently and keep my balance to be able to walk…
Manitowoc, WI Cycle4CMT
09/16/2023 @ 9:00 am – 12:00 pm – Join us at the Manitowoc, Wisconsin Cycle4CMT Cycle4CMT is a volunteer-led national fundraising campaign for the CMTA. By participating in this year-round campaign, you will be joining thousands of others across the country who want to improve the lives of those living with CMT. Funds raised by the Cycle4CMT campaign fuel the CMTA’s mission to […]
CMTA Spring 2025 Report | EMPOWERING INDEPENDENCE: SMALL TOOLS, BIG IMPACT
…the CMTA Gadget Store’s curated selection of practical tools to advancements in genetic therapies and clinical trials through CMTA’s Strategy To Accelerate Research (CMTA-STAR), every step forward brings us closer…
Actio Biosciences Doses First Participant in Phase I Clinical Trial | Future Phase Ib Clinical Trial to Focus on CMT2C
…“This Phase I clinical trial is an important step forward for the CMT2C community and our CMTA-STAR Alliance Partner, Actio Biosciences,” said CMTA CEO Sue Bruhn, PhD. “CMT2C is a…
Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003
…the data in collaboration with potential partners for licensing or acquisition of PXT-3003. The CMTA would particularly like to thank the members of the CMT community for taking part in…
Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR
…cause CMT2A and CMT2E (MFN2 and NEFL). To develop their gene editing technology, they used induced-pluripotent stem cells (iPSC) from CMT patients often referred to as “disease in a dish”…
CMTA Adds Drug Development Expert Martine Garnier to STAR Advisory Board
…CMT patients.” CMT is a progressive disorder of the peripheral nerves that causes people to lose the normal use of their feet and legs. Symptoms include foot deformity (very high…
Statement from CMTA’s Chief Executive Officer, Sue Bruhn, PhD
Dear Members of the CMT Community, The Charcot-Marie-Tooth Association (CMTA) continues to prioritize the well-being of the CMT community. Advocating for improved access to care as well as the acceleration…
CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy
First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth Association (CMTA) today announced that it participated in the Seed Series Extension syndicate for Armatus Bio, Inc. (Armatus). Armatus is…